The FDA on February 19, 2016 approved IBRANCE® in combination with FASLODEX® (Fulvestrant) for the treatment of women with hormone receptor (HR) positive, Human Epidermal growth factor Receptor 2 (HER2)-negative advanced or metastatic breast cancer, with disease progression following endocrine therapy. IBRANCE® capsules are a product of Pfizer, Inc.
Bottom Ad
Advertisement
Subscribe
